Publicaciones en las que colabora con OLGA MARÍA CRUZ LÓPEZ (9)

2023

  1. N-aryltetrahydroisoquinoline derivatives as HA-CD44 interaction inhibitors: Design, synthesis, computational studies, and antitumor effect

    European Journal of Medicinal Chemistry, Vol. 258

2022

  1. Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles

    Pharmaceutics, Vol. 14, Núm. 4

2019

  1. Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity

    ACS Omega, Vol. 4, Núm. 25, pp. 21620-21626

2010

  1. Evaluación de la implantación de un nuevo recurso didáctico -diapositivas dinámicas- en la asignatura de Química Orgánica en la Licenciatura de Farmacia

    Ars pharmaceutica, Vol. 51, Núm. 1, pp. 191-200

2008

  1. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines

    Current Medicinal Chemistry, Vol. 15, Núm. 25, pp. 2614-2631

  2. From 5-fluorouracil acyclonucleosides to benzo-fused six- and seven-membered rings linked to pyrimidine and purine bases: The shift from differentiating anticancer agents to apoptotic inducers

    Expert Opinion on Drug Discovery, Vol. 3, Núm. 10, pp. 1223-1235

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2005

  1. 1H and 13C spectral assignment of symmetrical bis[(4-aminosubstituted)quinolinium] derivatives

    Magnetic Resonance in Chemistry, Vol. 43, Núm. 12, pp. 1066-1071

  2. Symmetrical bis-quinolinium compounds: New human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line

    Journal of Medicinal Chemistry, Vol. 48, Núm. 9, pp. 3354-3363